Neovasc Initiates Patient Enrollment in COSIRA Trial of Reducer(TM) Product
for Refractory Angina

-- Controlled and Double-Blinded Clinical Study is Designed to Demonstrate the Efficacy of Reducer in Reducing Angina Symptoms --

TSX Venture Exchange: NVC

VANCOUVER, Sept. 20 /CNW/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients. The primary endpoint is efficacy in reducing angina symptoms after six months. The COSIRA study is being conducted under the supervision of Principal Investigator Dr. Stefan Verheye at the Antwerp Cardiovascular Institute/ZNA Middelheim in Antwerp, Belgium, who performed the first four cases for the study on the first day of patient enrollment last week.

The Neovasc Reducer is a novel implantable product designed to treat heart disease patients who suffer from refractory angina. Refractory angina is a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle. It currently affects over two million patients worldwide, who typically lead severely restricted lives. The incidence of refractory angina is growing, and current treatment options are limited.

The Neovasc Reducer is a unique device that is implanted in the coronary sinus vein using minimally invasive techniques. It is intended to provide relief of refractory angina symptoms by modulating blood flow in the coronary sinus and thereby increasing perfusion of oxygenated blood to areas of the heart muscle where it is needed most. Placement of the Reducer is performed using a minimally invasive percutaneous procedure that is similar to implanting a coronary stent and takes approximately 20 minutes.

In March, results from an initial clinical trial of the Reducer were presented at the American College of Cardiology 2010 annual meeting. The data from this trial showed that three years after implantation of the Reducer, the product was safe and the vast majority of the 15 patients tested continued to show measurable improvement in angina symptoms. These three-year results built on positive six-month data were previously reported in the Journal of the American College of Cardiology. The COSIRA trial has been designed to provide controlled, statistically significant data to further demonstrate the efficacy of the Reducer and to support regulatory applications to enable marketing of the product.

In addition to the Antwerp Cardiovascular Institute, the COSIRA trial is also initiating patient enrollment at Ziekenhuis Oost-Limburg Hospital in Genk, Belgium; Montreal Heart Institute and the University of Ottawa Heart Institute in Canada; and Maastricht University Medical Centre and Utrecht University Medical Center in the Netherlands. Enrollment is expected to be completed by mid-2011.

"We are optimistic that the clinical data from COSIRA will support the excellent results we have seen in our previous clinical studies and confirm that the Reducer offers a relatively straightforward and viable long-term treatment option for patients with refractory angina, who currently lack alternatives for relieving their symptoms and improving their quality of life," said Prof. Shmuel Banai, MD, Neovasc Medical Director. "We are very pleased to have attracted such a strong group of clinical investigators from high quality cardiovascular medical centers for this trial and look forward to sharing initial data from COSIRA in the coming year."

About Neovasc Inc.

Neovasc Inc. is a specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer(TM), a novel product in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and as key components in a variety of third-party medical products such as percutaneous heart valves. For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

For further information: Corporate contact: Neovasc Inc., Chris Clark, 604 248-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners, Barbara Lindheim, 212 918-4650